Scientists restored brain function in mice with Huntington’s disease by fixing glial cells – the brain’s overlooked helpers. Instead of repairing neurons, they healed the support system that keeps neurons alive, opening a new path for treating neurodegeneration.
For years, brain disorders such as Huntington’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis have been seen as neuronal problems. The goal was to protect neurons or replace them. But growing evidence suggests that the root of the problem – and the key to fixing it – may lie elsewhere.
Glial cells, long thought to be the brain’s passive support system, are emerging as powerful regulators of neuronal health. When they malfunction, the balance of neurotransmitters such as potassium and glutamate is lost. Neurons, even if genetically intact, begin to fail – not because of their own defects but because their environment turns toxic.
This shift has inspired a bold new strategy: replacing diseased glial cells with healthy ones. In a new study, researchers transplanted human glial progenitor cells – immature support cells that grow into functioning glia – into mice with Huntington’s disease.
“What this study shows is that we may not need to correct the genetic mutation directly,” says Steven A. Goldman, Professor at the Center for Translational Neuromedicine, University of Copenhagen, Denmark. “By replacing the glial environment, we can restore balance at the synapse, protect vulnerable neurons and buy critical time for the brain.”
The implications go well beyond Huntington’s if glial dysfunction underlies other neurodegenerative conditions.
“This strategy could offer a new route – one that stabilises the brain by healing its cellular neighbourhood.”
The overlooked cells behind brain disease
Huntington’s disease was long thought to be driven mainly by faulty neurons, but glial cells have now been shown to play a central role.
“A few years ago, we transplanted embryonic stem cell–derived glial progenitors carrying the Huntington mutation into healthy animals, and they developed symptoms of Huntington’s disease. That showed that the glial cells, in this case the astrocytes – star-shaped glial cells that help control the brain’s chemical balance – were really a big part of the pathology.”
Researchers found that astrocytes failed to keep brain chemicals in balance, creating a toxic environment for neurons. To test whether healthy glia could outcompete diseased ones, they made chimeric mice with both human and mouse glial cells.
“We transplanted in normal human glial progenitors, and the healthy cells replaced the mutant cells. That showed that this should work in people.”
Swapping sick brain cells for healthy ones
To test which cells worked best, the team compared three types of human glial progenitor cells – fetal, embryonic stem cell–derived and induced pluripotent stem cell–derived – by transplanting each into identical mice with Huntington’s.
“This direct comparison helped us to test which cells were most effective at reversing symptoms.”
The team did not stop at mice. They developed viruses that can target human glial progenitor cells, enabling them to manipulate and track these cells in living brains.
“This method enables us to reach virtually every glial cell in the brain. I think it represents a major advance for gene therapy.”
They also identified genetic targets that could eventually enable scientists to treat neurons directly – without glial cell transplants.
“That is one line of work we are doing now. We think that this strategy can be expanded to many neurodegenerative diseases and are pursuing it aggressively.”
From laboratory bench to patient treatment
The method resembles the surgical approach used in Parkinson’s trials – but instead of injecting neurons, the team delivered glial progenitor cells into the striatum, the brain region most affected by Huntington’s.
“You do it the same way, but here, we inject the glial progenitors into the striatum.”
“The cells came from embryonic stem cells, and the team refined their process to meet strict safety standards for human use. Early tests and even Unted States Food and Drug Administration review went well. But just as clinical trials were within reach, the biotech market collapsed – and the funding disappeared.”
Cell transplants bring brains back to life
What happened next surprised even the researchers. When the healthy glial progenitor cells were transplanted into severely affected Huntington’s model mice, the results were dramatic.
“Not all cell types worked equally well,” says Steven A. Goldman. “The glial cells from fetal and embryonic stem cells led to a dramatic rescue, whereas those from induced pluripotent stem cells – laboratory-grown cells reprogrammed from adult tissue and promising for personalised medicine – had little or no effect in the same animals.”
The findings raise a caution for personalised medicine: induced pluripotent stem cell–derived glial cells may be too immature – meaning that they do not yet behave like fully developed brain cells – to work effectively in the brain. They probably need further refinement to match the impact of fetal or embryonic sources.
“It was a whopping effect – the damaged neurons grew back complex branches, and the mice regained motor coordination that had seemed permanently lost. Even in a model of severe Huntington’s disease, the transplanted glial cells restored movement and extended survival.”
New cells spread and heal the brain
In the mouse experiments, the transplanted glial cells did not stay confined to where they were injected.
“The cells migrate. In mice, they end up taking over much of the forebrain. So this is potentially a more profound rescue.”
This wide migration occurred only with fetal and embryonic stem cell–derived glia. Induced pluripotent stem cell–derived cells stayed near the injection site, limiting their effect.
“What was really being fixed was not the neuron’s DNA – but its environment. If you correct potassium or glutamate uptake – in the neuron or astrocyte – it does not matter. That fixes the synapse. And we think that is happening here.”
Hopeful but careful steps toward treatment
Scientists caution that the therapy cannot halt Huntington’s disease altogether.
“This is not a cure by any means, but it is a way of substantially prolonging the life and viability of individual neurons – and therefore the neural networks – and therefore, we hope, of patients. The neurons remain far healthier – no longer overwhelmed by excess synaptic potassium. So they live longer. They function better. Even if you rescue the striatum, that might give somebody, for example, 7–10 years – but then the rest of the brain is going to be symptomatic.”
The team remains cautious: mice are not humans.
“It is one thing in a mouse and another in a person,” Goldman notes. Nevertheless, the findings open a wider horizon. Because glial imbalance is common in amyotrophic lateral sclerosis and Alzheimer’s disease, the same strategy could eventually extend far beyond Huntington’s disease. “We hope that this approach will not be limited to Huntington’s,” says Goldman. “If similar mechanisms are at play in other diseases, stabilising the glial environment could offer a broader path – preserving vulnerable brain networks by repairing the cellular neighbourhood they rely on. That is exactly what we are exploring now.”
